Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

医学 美罗华 滤泡性淋巴瘤 内科学 肿瘤科 长春新碱 人口 强的松 国际预后指标 环磷酰胺 外科 淋巴瘤 化疗 环境卫生
作者
Alessandro Pastore,Vindi Jurinović,Robert Kridel,Eva Hoster,Annette M. Staiger,Monika Szczepanowski,Christiane Pott,Nadja Kopp,Mark A. Murakami,Heike Horn,Ellen Leich,Alden A. Moccia,Anja Mottok,Ashwini Sunkavalli,Paul Van Hummelen,Matthew D. Ducar,Daisuke Ennishi,Hennady P. Shulha,Christoffer Hother,Joseph M. Connors
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (9): 1111-1122 被引量:613
标识
DOI:10.1016/s1470-2045(15)00169-2
摘要

Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed. We aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model.We did DNA deep sequencing to retrospectively analyse the mutation status of 74 genes in 151 follicular lymphoma biopsy specimens that were obtained from patients within 1 year before beginning immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These patients were recruited between May 4, 2000, and Oct 20, 2010, as part of a phase 3 trial (GLSG2000). Eligible patients had symptomatic, advanced stage follicular lymphoma and were previously untreated. The primary endpoints were failure-free survival (defined as less than a partial remission at the end of induction, relapse, progression, or death) and overall survival calculated from date of treatment initiation. Median follow-up was 7·7 years (IQR 5·5-9·3). Mutations and clinical factors were incorporated into a risk model for failure-free survival using multivariable L1-penalised Cox regression. We validated the risk model in an independent population-based cohort of 107 patients with symptomatic follicular lymphoma considered ineligible for curative irradiation. Pretreatment biopsies were taken between Feb 24, 2004, and Nov 24, 2009, within 1 year before beginning first-line immunochemotherapy consisting of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). Median follow-up was 6·7 years (IQR 5·7-7·6).We established a clinicogenetic risk model (termed m7-FLIPI) that included the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), the Follicular Lymphoma International Prognostic Index (FLIPI), and Eastern Cooperative Oncology Group (ECOG) performance status. In the training cohort, m7-FLIPI defined a high-risk group (28%, 43/151) with 5-year failure-free survival of 38·29% (95% CI 25·31-57·95) versus 77·21% (95% CI 69·21-86·14) for the low-risk group (hazard ratio [HR] 4·14, 95% CI 2·47-6·93; p<0·0001; bootstrap-corrected HR 2·02), and outperformed a prognostic model of only gene mutations (HR 3·76, 95% CI 2·10-6·74; p<0·0001; bootstrap-corrected HR 1·57). The positive predictive value and negative predictive value for 5-year failure-free survival were 64% and 78%, respectively, with a C-index of 0·80 (95% CI 0·71-0·89). In the validation cohort, m7-FLIPI again defined a high-risk group (22%, 24/107) with 5-year failure-free survival of 25·00% (95% CI 12·50-49·99) versus 68·24% (58·84-79·15) in the low-risk group (HR 3·58, 95% CI 2·00-6·42; p<0.0001). The positive predictive value for 5-year failure-free survival was 72% and 68% for negative predictive value, with a C-index of 0·79 (95% CI 0·69-0·89). In the validation cohort, risk stratification by m7-FLIPI outperformed FLIPI alone (HR 2·18, 95% CI 1·21-3·92), and FLIPI combined with ECOG performance status (HR 2·03, 95% CI 1·12-3·67).Integration of the mutational status of seven genes with clinical risk factors improves prognostication for patients with follicular lymphoma receiving first-line immunochemotherapy and is a promising approach to identify the subset at highest risk of treatment failure.Deutsche Krebshilfe, Terry Fox Research Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
豆花牛肉面完成签到,获得积分10
刚刚
pluto的应助被cycy采纳,获得50
刚刚
刚刚
袁有方发布了新的文献求助10
刚刚
元气发布了新的文献求助10
刚刚
老广发布了新的文献求助10
刚刚
顾矜的应助被Ximian采纳,获得10
刚刚
张张发布了新的文献求助10
1秒前
无极微光的应助被Ly采纳,获得20
1秒前
1秒前
威武的友琴完成签到,获得积分10
1秒前
2秒前
清pq发布了新的文献求助10
2秒前
高兴的新晴完成签到,获得积分10
2秒前
xm发布了新的文献求助10
2秒前
2秒前
3秒前
吃葡萄不吐葡萄皮的应助被小小采纳,获得100
3秒前
3秒前
xx驳回了顾矜的应助
3秒前
3秒前
3秒前
feifei完成签到,获得积分10
3秒前
看不懂文献的进士完成签到,获得积分10
3秒前
半拉馒头完成签到,获得积分10
4秒前
无名小卒完成签到,获得积分10
4秒前
sh发布了新的文献求助10
4秒前
SoilMan发布了新的文献求助10
4秒前
dairenfe发布了新的文献求助20
4秒前
伊莎贝儿发布了新的文献求助10
4秒前
珛生完成签到,获得积分10
4秒前
光亮澜完成签到,获得积分10
4秒前
dasilidanliya完成签到,获得积分20
5秒前
铭铭完成签到,获得积分10
5秒前
6611发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
小王完成签到,获得积分10
6秒前
隐形曼青的应助被无辜茗采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155073
求助须知:如何正确求助?哪些是违规求助? 9551529
关于积分的说明 21705228
捐赠科研通 7744266
什么是DOI,文献DOI怎么找? 3425957
关于科研通互助平台的介绍 2551109
邀请新用户注册赠送积分活动 2469734